All of this ultimately enhances the immunotherapy of the PD-L1 antibody, further inhibiting metastatic tumor growth and achieving a more effective anti-tumor effect, as well as inhibiting tumor metastasis (Wang M. et al., 2021). The gene discussed is CD274; the disease is neoplasm.